A liquid dressing includes a solvent and a film-forming polymer that is dissolved in the solvent and that is made by a process including: providing an alkoxy group-containing silicone resin which is obtained by subjecting an orthosilicate compound and an acidic aqueous solution to a hydrolysis and polymerization reaction; providing an isocyanate group-containing prepolymer which is obtained by reacting a diisocyanate compound with a hydrophilic polyether diol; and subjecting the alkoxy group-containing silicone resin and the isocyanate group-containing prepolymer to a polymerization reaction so as to obtain the film-forming polymer.

Natural honey and a surfactant are combined to achieve a novel wound treatment composition. The honey is chosen for its medicinal properties, and the surfactant is used for biofilm removal to enhance the effectiveness of the honey. In preferred embodiments, the honey is a tropical honey currently sourced from Mexico. The surfactant is mixed with water, then the aqueous mixture is combined with the honey. In accordance with a preferred embodiment, a surfactant powder is mixed with water at a ratio of 10% powder to water, then that mixture is combined with honey at a ratio greater than 50:50, more preferably at a ratio of 90:10. The currently preferred surfactant is Poloxamer 188. The product may be applied directly to a wound or applied to wound dressings including, without limitation, gauze, gauze rolls, hydrocolloids, and calcium alginate dressings.

Natural honey and a surfactant are combined to achieve a novel wound treatment composition. The honey is chosen for its medicinal properties, and the surfactant is used for biofilm removal to enhance the effectiveness of the honey. In preferred embodiments, the honey is a tropical honey currently sourced from Mexico. The surfactant is mixed with water, then the aqueous mixture is combined with the honey. In accordance with a preferred embodiment, a surfactant powder is mixed with water at a ratio of 10% powder to water, then that mixture is combined with honey at a ratio greater than 50:50, more preferably at a ratio of 90:10. The currently preferred surfactant is Poloxamer 188. The product may be applied directly to a wound or applied to wound dressings including, without limitation, gauze, gauze rolls, hydrocolloids, and calcium alginate dressings.

Devices for delivering a flowable tissue dressing material for treating a tissue site are described. The devices include a first zone including a first reactant, such as a polyol, and a second zone including a second reactant, such as a multi-isocyanate, which can be mixed together to form a flowable tissue dressing material. The device can also include a flowable tissue dressing material including a reacted polymer present in a carrier. Kits and methods including and/or using the devices are also described.

Disclosed herein are citrate-based mussel-inspired bioadhesives and methods of making and using the same. Also disclosed herein are methods of treating wounds.

Disclosed herein are citrate-based mussel-inspired bioadhesives and methods of making and using the same. Also disclosed herein are methods of treating wounds.

A method of promoting wound healing in a patient, the method comprising applying on a wound a biodegradable amino-acid based polymer.

Pharmaceutical compositions, more specifically poloxamer copolymer-based compositions and hyaluronic acid-based compositions, containing amelogenin, are useful for promoting periodontal or orthopedic soft or hard tissue regeneration, wound closure, and skin regeneration and rejuvenation. The composition can contain a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer in an amount of 18% to 30% by weight; amelogenin in an amount of 0.005% to 3% by weight; a disaccharide in an amount of 0.05% to 5% by weight; and an amino acid selected from alanine, glycine, isoleucine, leucine, proline, valine, and a mixture thereof in an amount of 0.05% to 5% by weight.

Pharmaceutical compositions, more specifically poloxamer copolymer-based compositions and hyaluronic acid-based compositions, containing amelogenin, are useful for promoting periodontal or orthopedic soft or hard tissue regeneration, wound closure, and skin regeneration and rejuvenation. The composition can contain a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer in an amount of 18% to 30% by weight; amelogenin in an amount of 0.005% to 3% by weight; a disaccharide in an amount of 0.05% to 5% by weight; and an amino acid selected from alanine, glycine, isoleucine, leucine, proline, valine, and a mixture thereof in an amount of 0.05% to 5% by weight.

A method and composite for treating a wound. A wound is sprayed with a composition that includes a volatile organic solvent, a biocompatible polymer and turmeric powder. The solvent evaporates during the spraying. The resulting composite stops bleeding instantly, can remain on the wound for prolonged periods and adheres with the wound, even under arterial pressure. The composite serves to promote wound healing and hemostasis in bleeding wounds.